combined therapy HBV and hdv infection caused by viruses

摘要

the application describes a composition containing the inhibitor u043au043eu0442u0440u0430u043du0441u043fu043eu0440u0442u0438u0440u0443u044eu0449u0435u0433u043e na + - u0442u0430u0443u0440u043eu0445u043eu043bu0430u0442 u043fu043eu043bu0438u043fu0435u043fu0442u0438u0434u0430 (NTCP) and another active ingredient selected from the group which u043eu0441u0442u043eu0438u0442 of u043du0443u043au043bu0435u043eu0437u0438u0434u043du043eu0433u043e counterpart, such as lamivudine, u0442u0435u043bu0431u0438u0432u0443u0434u0438u043d or u044du043du0442u0435u043au0430u0432u0438u0440, nucleotide analogue, such as tenofovir, u0430u0434u0435u0444u043eu0432u0438u0440 and u0438u043cu043cu0443u043du043eu043cu043eu0434u0443u043bu044fu0442u043eu0440u0430, such as interferon alpha.NTCP inhibitor inhibits the penetration of HBV / hdv in the cage, and preferably its pose on the basis of u043fu0435u043fu0442u0438u0434u0430 pre - s1 HBV. the application also describes the methods of treatment by HBV and hdv infection, hepatitis b and d or chronic hepatitis b and d.